Novo Nordisk ASWBO:NNO2 -1.23%71 Earnings per Share (Diluted) is €3.67 as of Mar. 2026. GuruFocus rates WBO:NNO2 with a GF Score™ of 71/100 and a GF Value™ of €120.14 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 786 Drug Manufacturers companies, Novo Nordisk AS ranks better than 72.39% on this metric.
Novo Nordisk AS's EPS (Basic) for the
three
months ended in Mar. 2026 was €1.46.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €3.68.
During the past 12 months, Novo Nordisk AS's average EPS without NRIGrowth Rate was -1.50% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 25.80% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 25.60% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 13.90% per year.
During the past 13 years, Novo Nordisk AS's highest 3-Year average EPS without NRI Growth Rate was 38.20% per year. The lowest was -2.90% per year. And the median was 18.80% per year.
Novo Nordisk AS (WBO:NNO2) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Novo Nordisk AS Earnings per Share (Diluted) Related Terms
Novo Nordisk AS Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Novo Nordisk AS's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS Earnings per Share (Diluted) Chart
WBO:NNO2 vs LLY, JNJ, ABBV: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's PE Ratio distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's PE Ratio falls into.
Novo Nordisk AS Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Novo Nordisk AS's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.67
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of €3.67 mean?
Novo Nordisk AS (WBO:NNO2) has a Earnings per Share (Diluted) of €3.67 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Novo Nordisk AS and its competitors. According to the industry distribution chart, Novo Nordisk AS ranks #217 out of 786 companies in the Drug Manufacturers industry, placing it in the top 27.6%.
Is Novo Nordisk AS's Earnings per Share (Diluted) too high?
Novo Nordisk AS's current Earnings per Share (Diluted) is €3.67. Based on the distribution chart, Novo Nordisk AS ranks #217 out of 786 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Novo Nordisk AS has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Earnings per Share (Diluted) compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novo Nordisk AS ranks #217 out of 786 companies for Earnings per Share (Diluted). This puts Novo Nordisk AS in the upper half of its industry. The industry median Earnings per Share (Diluted) is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.60, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Novo Nordisk AS and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Nordisk AS's current Earnings per Share (Diluted) is €3.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (WBO:NNO2) is currently considered Significantly Undervalued. The stock's GF Value™ is €120.14, compared to a current price of €43.06 — trading 64.2% below its estimated fair value. The current Earnings per Share (Diluted) is €3.67. Novo Nordisk AS's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Novo Nordisk AS (WBO:NNO2), the current Earnings per Share (Diluted) is €3.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (WBO:NNO2) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of €43.06 is trading 64.2% below its estimated GF Value™ of €120.14.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for WBO:NNO2:
Earnings per Share (Diluted): €3.67
GF Value™: €120.14 vs. price of €43.06 (64.2% below fair value)
No single metric tells the full story. See the WBO:NNO2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
71GF Score
Get the complete analysis for WBO:NNO2
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:NNO2 has been successfully added to your 
